On the trail of fugitive fat: the chase turns to NRTIs
- PMID: 11366871
On the trail of fugitive fat: the chase turns to NRTIs
Abstract
AIDS: Several research teams attended the 1st International Workshop on Adverse Drug Reactions and Liposdystrophy in HIV. Under discussion were the effects of reverse transcriptase (RT) inhibitors and nucleoside RT inhibitors (NRTIs) on lipodystrophy, also known as fat redistribution. Key findings included correlating lipodystrophy with long-term treatment by RTs, linking fat redistribution to Stavudine (d4T), and determining effects of various protease inhibitors which contribute to lipodystrophy. Results from an Italian study showed women were more likely than men to have fat abnormalities. An Australian research team presented a cohort study detailing risk factors for lipodystrophy. Harmful consequences of lipodystrophy were reviewed, such as increased cardiac risk due to elevated plasma triglycerides and cholesterol, and increased incidence of diabetes. The drawbacks of antiretroviral treatment tactics were also discussed. In addition, lipodystrophy treatments include aerobics and resistance training, injections of recombinant human growth hormone, and lipid-lowering drugs.
Similar articles
-
Lipodrama.Res Initiat Treat Action. 1999 Dec;5(5):13-5. Res Initiat Treat Action. 1999. PMID: 11366885
-
Drug reactions & lipodystrophy workshop.STEP Perspect. 1999 Fall;99(3):17-8. STEP Perspect. 1999. PMID: 11366865
-
Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.Antivir Ther. 2001 Sep;6(3):145-60. Antivir Ther. 2001. PMID: 11808750 Review.
-
Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.J HIV Ther. 2001 May;6(2):25-7. J HIV Ther. 2001. PMID: 11501199 No abstract available.
-
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.Lancet. 1999 Sep 25;354(9184):1112-5. doi: 10.1016/S0140-6736(99)06102-4. Lancet. 1999. PMID: 10509516 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical